Conserved internal influenza virus peptides

Conserved internal influenza virus peptides are highly stable amino acid sequences derived from the internal proteins of the influenza virus, most notably the Nucleoprotein (NP), Matrix protein 1 (M1), and the Polymerase complex (PA, PB1, PB2). Unlike the surface proteins Hemagglutinin and Neuraminidase, which undergo rapid antigenic evolution, these internal components remain largely unchanged across various strains and subtypes of Influenza A and B (Frontiers in Immunology, 2021). These peptides are utilized as therapeutic targets in the development of universal influenza vaccines to elicit broad-spectrum immunity. The primary mechanism of action involves the induction of cellular immune responses, specifically activating CD4+ and CD8+ T cells that recognize these conserved epitopes presented on the surface of infected cells (Vaccines, 2019). By targeting these internal regions, drugs like FLU-v and OVX313 aim to provide heterosubtypic protection, reducing the severity of illness and viral shedding regardless of the circulating strain (The Lancet Infectious Diseases, 2019). This approach addresses the limitations of seasonal vaccines, which require annual updates and offer little protection against pandemic shifts. Furthermore, these peptides are often delivered via viral vectors or as synthetic peptides with adjuvants to enhance their immunogenicity (NPJ Vaccines, 2020). Clinical trials have demonstrated that targeting these conserved regions can induce long-lasting T-cell memory, potentially offering multi-year protection against diverse influenza viruses (Science Translational Medicine, 2018).

Other names

Conserved influenza epitopesInternal viral antigensUniversal influenza vaccine targetsCross-reactive influenza peptidesT-cell influenza epitopes

Induction of cross-reactive T-cell mediated immunity (CD4+ and CD8+) against conserved viral epitopes to provide heterosubtypic protection.